Ewa Gogola

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5140318/publications.pdf

Version: 2024-02-01

567281 996975 3,537 14 15 15 citations h-index g-index papers 17 17 17 6070 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. Cell, 2018, 172, 373-386.e10.	28.9	1,201
2	Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature, 2016, 535, 382-387.	27.8	685
3	REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature, 2015, 521, 541-544.	27.8	487
4	EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nature Cell Biology, 2017, 19, 1371-1378.	10.3	257
5	Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality. Cancer Cell, 2018, 33, 1078-1093.e12.	16.8	238
6	BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance. Nature Methods, 2018, 15, 134-140.	19.0	110
7	The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells. Cell Reports, 2018, 23, 2107-2118.	6.4	110
8	Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8409-8414.	7.1	106
9	Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells. Nature Communications, 2017, 8, 15981.	12.8	83
10	Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas. Cell Reports, 2018, 23, 100-111.	6.4	60
11	Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated Cancer. Annual Review of Cancer Biology, 2019, 3, 235-254.	4.5	47
12	TRIM28 Is an Epigenetic Barrier to Induced Pluripotent Stem Cell Reprogramming. Stem Cells, 2017, 35, 147-157.	3.2	43
13	Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps. Molecular Cell, 2021, 81, 4692-4708.e9.	9.7	40
14	Studying cancer drug resistance using BRCA-deficient mouse mammary tumor organoids. Protocol Exchange, 0, , .	0.3	1